Liquid pharmaceutical composition
By adding an appropriate amount of divalent cation to the liquid pharmaceutical composition and using needleless injection technology, the problem of low gene expression efficiency of nucleic acid vaccines when lipid nanoparticles is not used, and efficient nucleic acid delivery and genes are achieved Enhanced expression.
Patent Information
- Application Number
- CN202380034568.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-20
- Filing Date
- 2023-04-20
- Publication Date
- 2024-11-26
AI Technical Summary
The prior art is difficult to improve the gene expression efficiency of nucleic acid vaccines without the use of lipid nanoparticles (LNPs), and there is a problem of insufficient physiological activity when injecting nucleic acid into cells without needle-free syringes.
By adding divalent cations, such as Mg2+, Ca2+, Mn2+, Zn2+, and a concentration of more than 0.0406 mM and less than 81.1 mM in total, it is injected into the injection object by spraying injection technology without an injection needle. , improve the physiological activity of nucleic acids and gene expression efficiency.
It is achieved to improve the physiological activity and gene expression efficiency of nucleic acids without using LNP, enhance the delivery efficiency and gene expression effect of nucleic acids in cells, especially when using needle-free syringes, significantly improve the enhancement effect of gene expression.
Smart Images

Figure CN119031920A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a liquid pharmaceutical composition. Background Art
[0002] In recent years, as for medical devices for administering liquid medicine, interest in needle-free syringes has increased from the perspectives of countermeasures for needle phobia, pursuit of usability, and reduction of infectious waste. Generally speaking, needle-free syringes are known to be syringes that use compressed gas or spring force as a driving force to squeeze liquid medicine from the top of a nozzle and administer the liquid medicine into a living body (Non-patent Document 1). In addition, a needle-free syringe that uses the combustion energy of ignition powder as injection energy has been developed (Patent Document 1).
[0003] The needle-free injector, which uses the combustion energy of the ignition powder as the ejection energy, can deliver the medicine to the nucleus and cytosol because the medicine is squeezed out instantly for administration. From the perspective of drug delivery systems (DDS), the usefulness of the needle-free injector has also attracted much attention, and has been studied in various drugs such as low molecules, peptides, proteins, antibodies, etc. with anticancer effects. In particular, in the field of vaccines and immunity, it has been reported that the needle-free injector can increase antibody titers and induce cellular immunity (non-patent literature 2).
[0004] In the field of vaccines, major breakthroughs have been made, such as the development of vaccines against the new coronavirus SARS-CoV-2. After the vaccine, which also uses mRNA as an active ingredient, showed high effectiveness in clinical trials (Non-Patent Document 3), it was used all over the world and had a great impact. The mRNA vaccine is a new treatment modality and is expected to be a technical singularity.
[0005] On the other hand, nucleic acid vaccines require very high expression of genes contained in nucleic acid when obtaining enough antibody titers. In the actual widely used nucleic acid vaccines for SARS-CoV-2, lipid nanoparticles (LipidNanoParticle, LNP) are used to improve gene expression. However, the new development of LNP not only requires a large amount of labor, but also has a large manufacturing cost. In addition, there are also concerns related to safety such as anaphylactic shock caused by the polyethylene glycol (PEG) used in LNP. Therefore, it is urgently desired to improve the technology of gene expression without using LNP. In addition, when using a needleless syringe to throw a nucleic acid containing gene to an injection object, the improvement of gene expression for realizing a degree comparable to LNP is also being carried out.
[0006] Prior art literature
[0007] Patent Literature
[0008] Patent Document 1: Japanese Patent Application Publication No. 2012-61269
[0009] Non-patent literature
[0010] Non-patent document 1: Clin. Cosmet. Investig. Dermatol., 2018 May 1; 11: 231-238 Non-patent document 2: AAPS PharmSciTech., 2019 Dec 9; 21(1): 19
[0011] Non-patent document 3: Ministry of Health, Labor and Welfare, Regarding Pfizer's new coronavirus vaccine, [online], [retrieved on March 11, 2022], Internet<https: / / www.mhlw.go.jp / stf / seisakunitsuite / bunya / vaccine_pfizer.html> Summary of the invention
[0012] Problems to be solved by the invention
[0013] The technical problem of the present disclosure is to provide at least the following: That is, to provide a technology capable of obtaining high physiological activity when a liquid pharmaceutical composition containing a nucleic acid that exerts physiological activity in an injection target is injected into the injection target.
[0014] Solutions for solving problems
[0015] The present inventors have found that the above technical problems can be solved by the following method: when a liquid pharmaceutical composition is injected into an injection object using an injector that injects the liquid pharmaceutical composition into the injection object without using an injection needle, the liquid pharmaceutical composition contains divalent cations, and the concentration of the divalent cations is set to a predetermined range in terms of total amount.
[0016] One embodiment of the present disclosure is a liquid pharmaceutical composition, wherein the liquid pharmaceutical composition comprises nucleic acids and divalent cations, the concentration of the divalent cations is greater than or equal to 0.0406 mM and less than 81.1 mM in total, and the liquid pharmaceutical composition is injected into an injection object using an injector that injects the liquid pharmaceutical composition into the injection object without using an injection needle.
[0017] As a preferred embodiment, in the liquid pharmaceutical composition, the divalent cation is selected from Mg 2+ , Ca 2+ , Mn 2 + and Zn 2+ One or more of the groups.
[0018] In addition, as a preferred embodiment, the liquid medical composition is injected into the injection target using an injector that injects the liquid medical composition into the injection target without using an injection needle, and is injected into the injection target by jet injection.
[0019] Furthermore, as a preferred embodiment, the liquid pharmaceutical composition is used for inducing cellular immunity.
[0020] Another embodiment of the present disclosure is an injector that injects a liquid medical composition into an injection target without using an injection needle, the injector comprising: a container that contains the liquid medical composition; a nozzle that is connected to the container, the nozzle having an ejection port for ejecting the liquid medical composition toward the injection target; and a pressurizing portion that pressurizes the liquid medical composition contained in the container during operation, thereby ejecting the liquid medical composition from the ejection port toward the injection target, the liquid medical composition comprising nucleic acids and divalent cations, the concentration of the divalent cations being greater than or equal to 0.0406 mM and less than 81.1 mM in total amount.
[0021] As a preferred solution, in the injector, the divalent cation is selected from Mg 2+ , Ca 2+ , Mn 2+ and Zn 2+ One or more of the groups.
[0022] In addition, another embodiment of the present disclosure is a method for injecting a liquid pharmaceutical composition into an injection object using an injector that injects the liquid pharmaceutical composition into the injection object without passing through an injection needle, wherein the liquid pharmaceutical composition contains nucleic acids and divalent cations, and the concentration of the divalent cations is greater than 0.0406 mM and less than 81.1 mM in total amount.
[0023] As a preferred embodiment, in the method, the divalent cation is selected from Mg 2+ , Ca 2+ , Mn 2+ and Zn 2+ One or more of the groups.
[0024] Beneficial Effects
[0025] The present disclosure can achieve at least the following effects: That is, it can achieve the following effect: a technology can be provided for obtaining high physiological activity when a liquid pharmaceutical composition containing a nucleic acid that exerts physiological activity in an injection target is injected into the injection target. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 It is a diagram showing a schematic structure of a syringe according to one embodiment of the present disclosure.
[0027] Figure 2 : is a graph showing the results of Test Example 1 and Comparative Test Example 1-1 according to one embodiment of the present disclosure.
[0028] Figure 3 : is a graph showing the results of Comparative Test Example 1-2 and Comparative Test Example 1-3 according to one embodiment of the present disclosure.
[0029] Figure 4 It is an image (photograph in place of the drawing) showing the results of Test Example 2 and Comparative Test Example 2 according to one embodiment of the present disclosure.
[0030] Figure 5 It is an image (photograph instead of a drawing) showing the results of Test Example 4, Comparative Test Example 4-1, Comparative Test Example 4-2, and Comparative Test Example 4-3 according to one embodiment of the present disclosure.
[0031] Figure 6 It is an image (photograph instead of a drawing) showing the results of Test Example 5 and Comparative Test Example 5 according to one embodiment of the present disclosure.
[0032] Figure 7 It is an image (photograph in place of the drawing) showing the results of Test Example 6 and Comparative Test Example 6 according to one embodiment of the present disclosure.
[0033] Figure 8 It is an image (photograph instead of a drawing) showing the results of Test Example 7 and Comparative Test Example 7 according to one embodiment of the present disclosure.
[0034] Fig. 9 It is an image (photograph instead of a drawing) showing the results of Test Example 8 and Comparative Test Example 8 according to one embodiment of the present disclosure.
[0035] Fig.10 It is an image (photograph instead of a drawing) showing the results of Test Example 9 and Comparative Test Example 9 according to one embodiment of the present disclosure.
[0036] Fig.11 It is an image (photograph instead of a drawing) showing the results of Test Example 10, Comparative Test Example 10-1, Comparative Test Example 10-2, and Comparative Test Example 10-3 according to one embodiment of the present disclosure.
[0037] Fig.12 (A) is an image (instead of a photograph of the drawing) of the results of Comparative Test Example 11-1, Comparative Test Example 11-2, Comparative Test Example 11-3, and Comparative Test Example 11-4 of one embodiment of the present disclosure. Fig.12(B) is an image (instead of a photograph of the drawing) of the results of Test Example 11 and Comparative Test Example 11-1 of one embodiment of the present disclosure. Fig.12 (C) is an image (instead of a photograph of the drawing) of the results of Comparative Test Example 11-2 and Comparative Test Example 11-5 of one embodiment of the present disclosure. DETAILED DESCRIPTION
[0038] Each configuration and their combination in each embodiment is an example, and the addition, omission, substitution and other changes of the configuration can be appropriately made within the scope of the main purpose of the present disclosure. The present disclosure is not limited to the embodiments but only to the claims. In addition, each scheme disclosed in this specification can also be combined with any other feature disclosed in this specification.
[0039] One embodiment of the present disclosure is a liquid pharmaceutical composition, wherein the liquid pharmaceutical composition comprises nucleic acids and divalent cations, the concentration of the divalent cations is 0.0406 mM or more and less than 81.1 mM in total, and the liquid pharmaceutical composition is injected into an injection object using an injector that injects the liquid pharmaceutical composition into the injection object without using an injection needle.
[0040] (Nucleic Acids)
[0041] The nucleic acid contained in the liquid pharmaceutical composition of the present embodiment is not particularly limited as long as it is a nucleic acid that exerts physiological activity in the injected subject.
[0042] The nucleic acid may be DNA or RNA. In addition, the nucleic acid may be a nucleic acid containing a protein-encoding portion or a nucleic acid not containing a protein-encoding portion (non-coding nucleic acid). In addition, the nucleic acid contained in the liquid pharmaceutical composition may be one or more.
[0043] Examples of the case where the nucleic acid includes a portion encoding a protein include the following.
[0044] For example, when the nucleic acid is a DNA containing a gene, it exhibits a physiological activity as a template for mRNA synthesis (transcription) for producing a protein, and the physiological activity can be quantitatively evaluated based on the amount of mRNA or protein produced.
[0045] Furthermore, when the nucleic acid is mRNA, it exhibits a physiological activity as a template for protein synthesis (translation), and its physiological activity can be quantitatively evaluated by the amount of protein produced.
[0046] In addition, the physiological activity can also be evaluated based on the changes in the injection object caused by the increase or decrease of the mRNA and protein produced. For example, the injection object is an injection object (such as an individual (organism), etc.) that can induce cellular immunity, and the nucleic acid is a nucleic acid encoding a protein that induces cellular immunity. By inducing the increase of the protein of the cellular immunity, in the case of such a change that cellular immunity is induced in the injection object, the nucleic acid exerts a physiological activity such as inducing cellular immunity, and its physiological activity can be quantitatively evaluated by the induction amount of the cellular immunity of the injection object. In addition, it can also be evaluated by the induction amount of the cellular immunity of the injection object after the restimulation (resensitization) caused by the protein that induces the cellular immunity.
[0047] Examples of the case where the nucleic acid does not contain a portion encoding a protein include the following.
[0048] For example, when the injection object is an individual (organism) to which a vaccine can be administered, if the nucleic acid is a DNA containing a CpG motif (CpG DNA) or polyinosinic acid-polycytidylic acid (PolyI:C), it exerts a physiological activity as an adjuvant for enhancing the effect of the vaccine, and its physiological activity can be quantitatively evaluated by anti-tumor effect (the effect can be evaluated, for example, by a reduction in tumor size), maturity of immune cells, etc.
[0049] Furthermore, when the nucleic acid is a small interfering RNA (siRNA), it exhibits physiological activity of degrading mRNA and sequence-specifically inhibiting the expression of a target gene, and its physiological activity can be quantitatively evaluated based on the amount of mRNA or protein produced by the target gene.
[0050] Furthermore, when the nucleic acid is antisense DNA or antisense RNA, it hybridizes with RNA of the target gene and exerts physiological activities such as inhibiting splicing or inhibiting translation, and the physiological activity can be quantitatively evaluated based on the amount of mRNA or protein produced by the target gene.
[0051] The nucleic acid in this embodiment exerts physiological activity in the injection object when injected into the injection object and exists stably. In addition, if there is no adverse effect such as destroying the injection object, it can be in a free form or in a form fixed on a carrier such as nanoparticles, or it can be modified, including a solvent, and its scheme is not particularly limited.
[0052] The nucleic acid may be a natural product or an artificially synthesized nucleic acid.
[0053] In the embodiments described below, as the nucleic acid, the following are listed: an embodiment using free plasmid DNA containing a GFP (Green Fluorescence Protein) gene and using the GFP gene as a reporter gene; an embodiment using mRNA encoding GFP as a reporter protein; and an embodiment using mRNA encoding ovalbumin (OVA).
[0054] When the DNA comprises a gene, it can be designed in the form of an expression cassette or an expression vector comprising the gene. Moreover, for example, the gene can also be configured under the control of a promoter suitable for the injection object and the injection site of the DNA to be injected. That is, known genetic engineering methods can be used in any scheme. For example, in the embodiments described later, an embodiment using a vector CMV-DASHER-GFP (manufactured by ATUM Co., Ltd.) comprising a GFP gene is listed as an expression vector. The plasmid vector is well known and can be obtained by those skilled in the art. The subcloning of expression vectors and recombinant vectors can be carried out according to known methods.
[0055] In the present embodiment, "capable of obtaining high physiological activity when a liquid pharmaceutical composition containing a nucleic acid that exerts physiological activity in the injection object is injected into the injection object" means that, when the physiological activity exerted by the nucleic acid is evaluated by a quantitative index, the physiological activity exerted by the nucleic acid (the physiological activity may be, for example, an amount indicating the physiological activity) is greater when a liquid pharmaceutical composition containing a nucleic acid and having a divalent cation concentration within the specified range described later is injected in the same manner as above, compared to when a liquid pharmaceutical composition containing a nucleic acid and having a divalent cation concentration within the specified range described later is injected into the injection object using an injector that injects the liquid pharmaceutical composition into the injection object without via an injection needle.
[0056] That is, for example, when a liquid pharmaceutical composition containing a nucleic acid and having a total concentration of divalent cations of less than 0.0406 mM and not less than 81.1 mM is injected into an injection target using an injector that injects the liquid pharmaceutical composition into the injection target without an injection needle (referred to as Scheme B), the physiological activity exerted by the nucleic acid is set to "Activity B", and when the liquid pharmaceutical composition is injected into the injection target in the same manner as above (referred to as Scheme A) under the same conditions as Scheme B except that the liquid pharmaceutical composition containing a nucleic acid and having a total concentration of divalent cations of not less than 0.0406 mM and not more than 81.1 mM, the physiological activity exerted by the nucleic acid is set to "Activity A", Activity B<Activity A.
[0057] Furthermore, in the present embodiment, “high physiological activity can be obtained when a liquid pharmaceutical composition containing a nucleic acid that exerts a physiological activity in the injection subject is injected into the injection subject” means that, when the physiological activity exerted by the nucleic acid is evaluated by a quantitative index, the physiological activity exerted by the nucleic acid (the physiological activity may be, for example, an amount indicating the physiological activity) is greater when a liquid pharmaceutical composition containing a nucleic acid and having a total concentration of divalent cations within a prescribed range described later is injected into the injection subject using an injector that injects the liquid pharmaceutical composition into the injection subject without using an injection needle than when a liquid pharmaceutical composition containing a nucleic acid and having a total concentration of divalent cations within a prescribed range described later is injected into the injection subject using a syringe with a needle.
[0058] That is, for example, when a liquid pharmaceutical composition containing a nucleic acid and having a total divalent cation concentration of 0.0406 mM or more and less than 81.1 mM is injected into an injection subject using a syringe with a needle (referred to as Scheme C), the physiological activity exerted by the nucleic acid is set to “Active C”, and when the physiological activity exerted by the nucleic acid is set to “Active A” under the same conditions as Scheme C except that a liquid pharmaceutical composition containing a nucleic acid and having a total divalent cation concentration of 0.0406 mM or more and less than 81.1 mM is injected into the injection subject using an injector that injects the liquid pharmaceutical composition into the injection subject without using an injection needle (referred to as Scheme A), the activity C<activity A.
[0059] When the physiological activity of the nucleic acid is evaluated by a quantitative index (e.g., expression level, cellular immunity induction level, antitumor effect, immune cell maturity, etc.), the quantitative index may be appropriately set according to the physiological activity of the nucleic acid.
[0060] For example, when the nucleic acid is DNA, i.e., contains a gene, the quantitative index may include the amount of mRNA produced using it as a template, the amount of protein produced using the mRNA as a template (usually evaluated as the expression level of the gene), etc.
[0061] Furthermore, for example, when the nucleic acid is mRNA, examples thereof include the amount of protein produced using the mRNA as a template.
[0062] That is, for example, when the nucleic acid is DNA, that is, contains a gene, and when the quantitative index is the expression level of the gene, when a liquid pharmaceutical composition having a total concentration of divalent cations of less than 0.0406 mM and 81.1 mM or more is injected into the injection object using an injector that injects the liquid pharmaceutical composition into the injection object without an injection needle (referred to as Scheme B1), the expression level of the gene is set to "expression level B1", and when the conditions are the same as Scheme B1 except that the total concentration of divalent cations is set to 0.0406 mM or more and less than 81.1 mM, and the expression level of the gene is injected into the injection object in the same manner as above (referred to as Scheme A1), the expression level B1<expression level A1.
[0063] Furthermore, when the expression level of the gene is set to "expression level C1" when a liquid pharmaceutical composition having a total divalent cation concentration of 0.0406 mM or more and less than 81.1 mM is injected into an injection subject using a syringe with a needle (referred to as Scheme C1), and when the expression level of the gene is set to "expression level A1" under the same conditions as Scheme C1 except that a liquid pharmaceutical composition having a total divalent cation concentration of 0.0406 mM or more and less than 81.1 mM is injected into an injection subject using an injector that injects the liquid pharmaceutical composition into the injection subject without an injection needle (referred to as Scheme A1), the expression level C1<expression level A1.
[0064] Furthermore, with respect to the quantitative index, for example, when the nucleic acid is a nucleic acid encoding a protein that induces cellular immunity and the quantitative index is the induction amount of cellular immunity, when a liquid pharmaceutical composition having a total concentration of divalent cations of less than 0.0406 mM and 81.1 mM or more is injected into an injection target using an injector that injects the liquid pharmaceutical composition into the injection target without an injection needle (referred to as Scheme B2), the induction amount of cellular immunity is set to "induction amount B1", and when the same conditions as Scheme B1 are used except that the total concentration of divalent cations is set to 0.0406 mM or more and less than 81.1 mM, and the induction amount of cellular immunity is injected into the injection target in the same manner as above (referred to as Scheme A1), the induction amount of cellular immunity is set to "induction amount A1", then induction amount B1<induction amount A1.
[0065] This relationship is also the same with respect to the amount of cellular immunity induced in the injected subject after restimulation (resensitization) of the protein that induces cellular immunity.
[0066] The induction amount of cellular immunity may be any amount that indicates the degree of induction of cellular immunity, and may be, for example, the number of spots when an ELISpot (enzyme-linked immunosorbent spot) kit is used as in the examples described below.
[0067] Furthermore, when a liquid pharmaceutical composition having a total divalent cation concentration of 0.0406 mM or more and less than 81.1 mM is injected into an injection subject using a syringe with a needle (referred to as Scheme C1), the induction amount of the cellular immunity is set to "induction amount C1", and when the same conditions as Scheme C1 are used except that a liquid pharmaceutical composition having a total divalent cation concentration of 0.0406 mM or more and less than 81.1 mM is injected into an injection subject using an injector that injects the liquid pharmaceutical composition into the injection subject without an injection needle (referred to as Scheme A1), the induction amount of the cellular immunity is set to "induction amount A1", the induction amount C1<induction amount A1.
[0068] This relationship is also the same with respect to the amount of cellular immunity induced in the injected subject after restimulation (resensitization) of the protein that induces cellular immunity.
[0069] As a method for evaluating the quantitative index, for example, after injecting the liquid pharmaceutical composition into an injection subject, the method can be appropriately selected using all or part of the injection subject according to the physiological activity exerted by the nucleic acid.
[0070] For example, as in the embodiments described later, when the injection object is an individual (organism), the nucleic acid is a DNA containing a gene, and the expression level of the gene in the vicinity of the injection site (i.e., a part of the injection object) is evaluated, after the liquid pharmaceutical composition is injected into the injection object, the vicinity of the injection site is obtained and appropriately selected according to the physiological activity exerted by the nucleic acid.
[0071] In addition, as in the examples described below, samples can be prepared by known methods, and the physiological activity exerted by the nucleic acid can be evaluated by the amount of protein produced. In the examples described below, since the protein produced is GFP protein, the physiological activity is evaluated by fluorescence brightness as an indicator.
[0072] In addition, for example, as in the embodiments described later, when the injection target is an individual (organism), the nucleic acid is a nucleic acid encoding a protein that induces cellular immunity, and the induction amount of cellular immunity is to be evaluated, after the liquid pharmaceutical composition is injected into the injection target, the induction amount of cellular immunity can be evaluated using the individual (organism) itself (i.e., the entire injection target) and using a known method for evaluating the induction amount of cellular immunity.
[0073] Furthermore, in the present embodiment, when a liquid pharmaceutical composition containing a nucleic acid that exerts a physiological activity in a subject of injection is injected into the subject of injection, the physiological activity obtained can be exerted for a long period of time.
[0074] The timing at which the physiological activity is exerted varies depending on the type of the nucleic acid, the injection target, the physiological activity exerted by the nucleic acid in the injection target, etc., but generally, the physiological activity is exerted after a predetermined time has passed from the time the liquid pharmaceutical composition is injected into the injection target.
[0075] The time when the physiological activity begins to be exerted (starting period) is preferably as early as possible from the time when the liquid pharmaceutical composition is injected into the injection object, for example, 6 hours after the time when the liquid pharmaceutical composition is injected into the injection object. On the other hand, the time when the physiological activity ends (ending period) is preferably as late as possible from the time when the liquid pharmaceutical composition is injected into the injection object, for example, 1 day, 2 days, 3 days, 5 days, 7 days, 14 days after the time when the liquid pharmaceutical composition is injected into the injection object.
[0076] (Divalent cation)
[0077] When the total amount of the concentration of divalent cations in the liquid pharmaceutical composition of the present embodiment is within a prescribed range, when the liquid pharmaceutical composition is injected into an injection target using an injector that injects the liquid pharmaceutical composition into the injection target without using an injection needle, a higher physiological activity can be obtained compared to the case of injecting a conventional liquid pharmaceutical composition.
[0078] The lower limit of the specified range is, for example, 0.0406 mM or more, 0.203 mM or more, 0.406 mM or more, 0.492 mM or more, 2.03 mM or more, 3.47 mM or more, 3.9 mM or more, 4.06 mM or more, 4.15 mM or more, 4.92 mM or more, 6.8 mM or more, 40.6 mM or more, and 49.2 mM or more.
[0079] The mechanism by which the liquid pharmaceutical composition is injected into a subject to obtain high physiological activity is not clear, but is presumed as follows. It should be noted that the present disclosure is not limited to the following presumption.
[0080] It is well known that nucleic acids have the function of inducing charge cross-linking and aggregation when coexisting with divalent cations such as magnesium ions in nucleic acid research and research on chromosome condensation during cell division using an atomic force microscope (AFM).
[0081] On the other hand, in terms of delivering nucleic acid into cells by injecting a liquid pharmaceutical composition into an injector for an injection object without an injection needle, it is achieved by injecting instantly and applying high energy to physically pass the nucleic acid through the cell membrane. The structure of the cell membrane is a phospholipid bilayer membrane. When nucleic acid physically passes through the cell membrane, it is different from the case of adsorption to the cell membrane via a receptor, and it is clear that steric hindrance such as particle size has a great influence on the efficiency of passing through. As a fact, it is reported that the direct penetration of the cell membrane of nanoparticles is preferably a small particle size.
[0082] From the above, it is speculated that the coexistence of nucleic acid and divalent cation causes the coarsening of nucleic acid and the reduction of hydrodynamic diameter, thereby improving the delivery efficiency of nucleic acid into cells. In addition, it is speculated that when an injector is used that injects a liquid pharmaceutical composition into an injection target without using an injection needle, the delivery efficiency of nucleic acid into cells is improved, and high physiological activity can be obtained.
[0083] Based on the above speculation: when the injection target is a cell or contains a cell, if the total amount of the divalent cation concentration is large, the nucleic acid is easily coarsened and the hydrodynamic diameter is easily reduced, and as a result, the amount of nucleic acid injected into the cell is easily increased, and high physiological activity is easily obtained. On the other hand, if the total amount of the divalent cation concentration is small, the nucleic acid is not easily coarsened and the hydrodynamic diameter is not easily reduced, and as a result, the amount of nucleic acid injected into the cell is not easily increased, and high physiological activity is difficult to obtain.
[0084] In addition, the upper limit of the specified range is, for example, less than 81.1 mM, less than 49.2 mM, less than 40.6 mM, less than 6.8 mM, less than 4.92 mM, less than 4.15 mM, less than 4.06 mM, less than 3.9 mM, less than 3.47 mM, less than 2.03 mM, less than 0.492 mM, less than 0.406 mM, or less than 0.203 mM.
[0085] When the total concentration of the divalent cations is small, the load on the injection target caused by the injection of the liquid pharmaceutical composition can be minimized. For example, when the injection target is a cell or contains cells, cell damage or death can be minimized.
[0086] In view of the reason for adopting the upper limit and the reason for adopting the lower limit, the upper limit and the lower limit of the prescribed range may be a non-contradictory combination selected from the above-mentioned upper limit examples and lower limit examples.
[0087] For example, it may be 0.0406 mM or more and less than 81.1 mM, 0.0406 mM or more and less than 49.2 mM, 0.0406 mM or more and less than 40.6 mM, 0.0406 mM or more and less than 6.8 mM, 0.0406 mM or more and less than 4.92 mM, 0.0406 mM or more and less than 4.15 mM, 0.0406 mM or more and less than 4.06 mM, 0.0406 mM or more and less than 3.9 mM, 0.0406 mM or more and less than 3.47 mM, 0.0406 mM or more and less than 2.03 mM, 0.0406 mM or more and less than 0.492 mM, 0.0406 mM or more and less than 0.406 mM, or 0.0406 mM or more and less than 0.203 mM.
[0088] In addition, for example, it can be 0.203mM or more and less than 81.1mM, 0.203mM or more and 49.2mM or less, 0.203mM or more and 40.6mM or less, 0.203mM or more and 6.8mM or less, 0.203mM or more and 4.92mM or less, 0.203mM or more and 4.15mM or less, 0.203mM or more and 4.06mM or less, 0.203mM or more and 3.9mM or less, 0.203mM or more and 3.47mM or less, 0.203mM or more and 2.03mM or less, 0.203mM or more and 0.492mM or less, or 0.203mM or more and 0.406mM or less.
[0089] In addition, for example, it can be 0.406mM or more and less than 81.1mM, 0.406mM or more and 49.2mM or less, 0.406mM or more and 40.6mM or less, 0.406mM or more and 6.8mM or less, 0.406mM or more and 4.92mM or less, 0.406mM or more and 4.15mM or less, 0.406mM or more and 4.06mM or less, 0.406mM or more and 3.9mM or less, 0.406 or more and 3.47mM or less, 0.406mM or more and 2.03mM or less, or 0.406mM or more and 0.492mM or less.
[0090] In addition, for example, it can be 0.492 or more and less than 81.1mM, 0.492mM or more and 49.2mM or less, 0.492mM or more and 40.6mM or less, 0.492mM or more and 6.8mM or less, 0.492mM or more and 4.92mM or less, 0.492mM or more and 4.15mM or less, 0.492mM or more and 4.06mM or less, 0.492mM or more and 3.9mM or less, 0.492mM or more and 3.47mM or less, or 0.492mM or more and 2.03mM or less.
[0091] In addition, for example, it can be greater than 2.03mM and less than 81.1mM, greater than 2.03mM and less than 49.2mM, greater than 2.03mM and less than 40.6mM, greater than 2.03mM and less than 6.8mM, greater than 2.03mM and less than 4.92mM, greater than 2.03mM and less than 4.15mM, greater than 2.03mM and less than 4.06mM, greater than 2.03mM and less than 3.9mM, or greater than 2.03mM and less than 3.47mM.
[0092] In addition, for example, it can be 3.47mM or more and less than 81.1mM, 3.47mM or more and 49.2mM or less, 3.47mM or more and 40.6mM or less, 3.47mM or more and 6.8mM or less, 3.47mM or more and 4.92mM or less, 3.47mM or more and 4.15mM or less, 3.47mM or more and 4.06mM or less, or 3.47mM or more and 3.9mM or less.
[0093] In addition, for example, it can be 3.9 mM or more and less than 81.1 mM, 3.9 mM or more and 49.2 mM or less, 3.9 mM or more and 40.6 mM or less, 3.9 mM or more and 6.8 mM or less, 3.9 mM or more and 4.92 mM or less, 3.9 mM or more and 4.15 mM or less, or 3.9 mM or more and 4.06 mM or less.
[0094] For example, it may be 4.06 mM to less than 81.1 mM, 4.06 mM to 49.2 mM, 4.06 mM to 40.6 mM, 4.06 mM to 6.8 mM, 4.06 mM to 4.92 mM, or 4.06 mM to 4.15 mM.
[0095] For example, it may be 4.15 mM or more and less than 81.1 mM, 4.15 mM or more and 49.2 mM or less, 4.15 mM or more and 40.6 mM or less, 4.15 mM or more and 6.8 mM or less, or 4.15 mM or more and 4.92 mM or less.
[0096] Furthermore, for example, it may be 4.92 mM or more and less than 81.1 mM, 4.92 mM or more and 49.2 mM or less, 4.92 mM or more and 40.6 mM or less, or 4.92 mM or more and 6.8 mM or less.
[0097] Furthermore, for example, it may be 6.8 mM or more and less than 81.1 mM, 6.8 mM or more and 49.2 mM or less, or 6.8 mM or more and 40.6 mM or less.
[0098] Furthermore, for example, it may be 40.6 mM or more and less than 81.1 mM, or 40.6 mM or more and 49.2 mM or less.
[0099] Furthermore, for example, it may be 49.2 mM or more and less than 81.1 mM.
[0100] Examples of the divalent cations include Mg and 2+ , Ca 2+ , Ba 2+ , Cu 2+ , Fe 2+ , Mn 2+ 、Zn 2+ etc., preferably Mg 2+ , Ca 2+ , Mn 2+ 、Zn 2+ In addition, the divalent cation contained in the liquid pharmaceutical composition may be one type or multiple types.
[0101] The supply source of the divalent cations may be a "salt" that generates the divalent cations when dissolved in a solvent. Examples of the salt include hydrochlorides, sulfates, nitrates, aspartates, acetates, lactates, gluconates, etc. In addition, the supply source of the divalent cations may be in the form of a hydrate.
[0102] As Mg 2+ Examples of the magnesium source include magnesium chloride, magnesium sulfate, magnesium nitrate, magnesium aspartate, magnesium acetate, magnesium lactate, and magnesium gluconate. From the viewpoint of versatility, magnesium chloride, magnesium sulfate, magnesium nitrate, and magnesium aspartate are preferred.
[0103] As Ca 2+ Examples of the calcium source include calcium chloride, calcium sulfate, calcium nitrate, calcium aspartate, calcium acetate, calcium lactate, and calcium gluconate. Calcium chloride is preferred from the viewpoint of versatility.
[0104] As Ba 2+Examples of the barium source include barium chloride, barium sulfate, barium nitrate, barium aspartate, barium acetate, barium lactate, and barium gluconate.
[0105] As Cu 2+ Examples of the copper source include copper (II) chloride, copper (II) sulfate, copper (II) nitrate, copper (II) aspartate, copper (II) acetate, copper (II) lactate, and copper (II) gluconate.
[0106] As Fe 2+ Examples of the iron source include iron (II) chloride, iron (II) sulfate, iron (II) nitrate, iron (II) aspartate, iron (II) acetate, iron (II) lactate, and iron (II) gluconate.
[0107] As Mn 2+ Examples of the manganese source include manganese (II) chloride, manganese (II) sulfate, manganese (II) nitrate, manganese (II) aspartate, manganese (II) acetate, manganese (II) lactate, and manganese (II) gluconate. From the viewpoint of versatility, manganese (II) sulfate is preferred.
[0108] As Zn 2+ Examples of the zinc source include zinc chloride, zinc sulfate, zinc nitrate, zinc aspartate, zinc acetate, zinc lactate, and zinc gluconate.
[0109] (Injection object)
[0110] The injection object in this embodiment can be, for example, one or more selected from the group consisting of cells, cell sheets, cell clusters, tissues, organs (skin, organs, etc.), organ systems, individuals (organisms), etc., without limitation. It can be any type represented by an in vitro system, an in vivo system, or an ex vivo system. The cell cluster can be a cell cluster obtained by three-dimensional culture, and the organ (skin, organs, etc.) can be an organoid.
[0111] In addition, when the injection object is injected, it is also possible to inject into the lower level contained in the object. That is, for example, when an individual (organism) is used as the injection object, it is possible to inject into the tissue contained in the individual (organism), it is also possible to inject into the cells contained in the individual (organism), or it is also possible to inject into both. In addition, when a tissue is used as the injection object, it is possible to inject into the cells contained in the tissue, it is possible to inject into the intercellular matrix contained in the tissue, or it is also possible to inject into both.
[0112] In addition, when the injection object in the present embodiment is one or more selected from the group consisting of cells, cell sheets, cell clusters, tissues, organs (skin, organs, etc.), and organ systems, it can be one or more selected from the group consisting of cells, cell sheets, cell clusters, tissues, organs (skin, organs, etc.), and organ systems in a state existing in an individual (organism), or it can be one or more selected from the group consisting of cells, cell sheets, cell clusters, tissues, organs (skin, organs, etc.), and organ systems in a state not existing in an individual (organism) (for example, a state of being removed and separated from an individual (organism), or a state of being produced outside an individual (organism)).
[0113] In addition, the injection object in this embodiment can also be selected from one or more of the group consisting of cells, cell sheets, cell clusters, tissues, organs (skin, organs, etc.), and organ systems derived from stem cells such as iPS cells (artificial pluripotent stem cells), which can be present in an individual (organism) or not in an individual (organism) (for example, a state of being removed and separated from an individual (organism), or a state of being made outside an individual (organism)). The cell cluster can be a cell cluster obtained by three-dimensional culture, and the organ (skin, organ, etc.) can be an organoid.
[0114] The individual (organism) is preferably a mammalian individual (organism). The mammal is not particularly limited, and humans can be listed, and mammals other than humans can be listed. Mammals other than humans include mice, rats, guinea pigs, hamsters, cattle, goats, sheep, pigs, monkeys, dogs, cats, etc.
[0115] Furthermore, regardless of which of the above-mentioned types are the injection targets in this embodiment, when injected into cells, the injection may be into the cytoplasm of the cell, into the nucleus of the cell, or into both the cytoplasm and the nucleus of the cell.
[0116] In addition, the injection object in this embodiment is not particularly limited, and is preferably one or more selected from the group consisting of intradermal, subcutaneous, and the muscle layer below the skin of a mammalian individual (organism). In this case, the liquid pharmaceutical composition can be injected from the injector toward the skin surface and injected into the skin, and injected into the skin, and one or more selected from the group consisting of intradermal, subcutaneous, and the muscle layer below the skin.
[0117] (Liquid pharmaceutical composition)
[0118] In the liquid pharmaceutical composition of the present embodiment, the nucleic acid and the divalent cation may be dissolved in a pharmacologically acceptable liquid (solvent). Examples of the pharmacologically acceptable liquid include water (e.g., water for injection), a buffer solution using phosphate (e.g., a phosphate buffer, a phosphate buffered saline solution (PBS) (which may be PBS(+) or PBS(-)), and the like.
[0119] It should be noted that, in the present disclosure, “dissolve” may be “suspend” or “emulsify”, “solution” may be “suspension” or “emulsion”, and “solvent” may be “suspending agent” or “emulsifier”.
[0120] The liquid pharmaceutical composition of the present embodiment may be mixed with a non-toxic carrier for pharmaceutical compositions in addition to the nucleic acid and the divalent cation. Examples of such carriers include glucose, lactose, sucrose, starch, mannitol, dextrin, fatty acid glycerides, polyethylene glycol, hydroxyethyl starch, ethylene glycol, polyoxyethylene sorbitan fatty acid esters, amino acids, gelatin, albumin, water, physiological saline, and the like. In addition, conventional additives such as stabilizers, wetting agents, emulsifiers, binders, and isotonic agents may be appropriately added as needed.
[0121] The content of the nucleic acid relative to the total amount of the liquid pharmaceutical composition of this embodiment can be appropriately set based on the type of the nucleic acid, the injection target, the physiological activity of the nucleic acid in the injection target, etc. In addition, the content of the divalent cation can also be appropriately set in consideration.
[0122] In addition, the injection amount of the liquid pharmaceutical composition into the injection object can be appropriately set based on the content or type of the nucleic acid, the injection object, the physiological activity of the nucleic acid in the injection object injected with the nucleic acid, etc. In addition, the injection amount of the divalent cation can also be appropriately set in consideration.
[0123] The pH of the liquid pharmaceutical composition of the present embodiment is not particularly limited as long as the nucleic acid exhibits physiological activity and stably exists in the injection object when the liquid pharmaceutical composition is injected into the injection object using an injector that injects the liquid pharmaceutical composition into the injection object without using an injection needle, and there is no adverse effect such as damaging the injection object.
[0124] The liquid pharmaceutical composition of this embodiment may be in the form of a vaccine.
[0125] The liquid pharmaceutical composition of this embodiment is preferably used for inducing cellular immunity. In this case, the injection object can be an injection object (such as an individual (organism) etc.) that can induce cellular immunity. The nucleic acid can be a nucleic acid encoding a protein that induces cellular immunity. In the examples described below, ovalbumin (OVA) is used as the protein that induces the cellular immunity, but cellular immunity is an immune response to foreign matter, and the protein that induces cellular immunity is not limited to OVA.
[0126] The induction of cellular immunity may be a secondary phenomenon caused by the induction of cellular immunity, for example, it may be the induction of the production of interferon γ (IFN-γ).
[0127] (Injector)
[0128] As the injector in this embodiment, an injector capable of injecting the liquid pharmaceutical composition into the injection object without using an injection needle can be used. That is, the liquid pharmaceutical composition can be injected into the injection object using an injector capable of injecting the liquid pharmaceutical composition into the injection object without using an injection needle.
[0129] In the injector of this embodiment, the "top side" refers to the side where the ejection port for ejecting the liquid pharmaceutical composition from the injector is arranged, and the "base side" refers to the side opposite to the top side in the injector, and these expressions do not limit the specific parts or positions.
[0130] In the injector in the present embodiment, in order to eject the liquid medical composition to the injection object, the driving unit imparts the injection energy. The "injection" achieved by the injector in the present embodiment is achieved by pressurizing the liquid medical composition contained in the containing part by the pressurizing part using the injection energy imparted by the driving unit, thereby causing the liquid medical composition to flow through the flow path of the containing part. As the injection energy, it can be the injection energy used in the previous injector, for example, the combustion energy of gunpowder, the generation energy of gas generating agent, the electrical energy of piezoelectric element, the mechanical energy of spring, etc., and in addition, the energy formed by appropriately combining these forms of energy can be used.
[0131] When the combustion energy of the gunpowder is used as the injection energy, the gunpowder includes, for example, a gunpowder containing zirconium and potassium perchlorate (ZPP), a gunpowder containing titanium hydride and potassium perchlorate (THPP), a gunpowder containing titanium and potassium perchlorate (TiPP), a gunpowder containing aluminum and potassium perchlorate (APP), a gunpowder containing aluminum and bismuth oxide (ABO), a gunpowder containing aluminum and molybdenum oxide (AMO), a gunpowder containing aluminum and copper oxide (ACO), a gunpowder containing aluminum and iron oxide (AFO), or a gunpowder containing a combination of multiple thereof. As a feature of these gunpowders, even if the combustion product thereof is gaseous at high temperature, it does not contain gaseous components at room temperature, so the combustion product condenses immediately after ignition. Thus, in the pressurization process for injecting the liquid pharmaceutical composition, the temperature of the combustion product during pressurization can be shifted to near room temperature in a short time after the pressure applied to the liquid pharmaceutical composition reaches the first peak injection force by the combustion of the ignition powder.
[0132] In addition, when the generation energy of the gas generating agent is used as the injection energy, a single-base smokeless gunpowder (for example, a single-base smokeless gunpowder containing 98 mass % of nitrocellulose, 0.8 mass % of diphenylamine, and 1.2 mass % of potassium sulfate) or various gas generating agents used in gas generators for air bags or gas generators for seat belt pretensioners can also be used as the gas generating agent.
[0133] In the injector of this embodiment, the pressurizing portion pressurizes the liquid medical composition contained in the containing portion during operation, thereby causing the liquid medical composition to be ejected from the ejection port toward the injection target.
[0134] The pressurization by the pressurizing unit is not particularly limited as long as it does not damage the system, such as damaging the housing unit, and the pressurization conditions of a normal injector can be adopted.
[0135] The pressure refers to the pressure inside the receiving part. There is no particular limitation on the measuring method, and for example, the measurement can be performed as described below. That is, as in the measuring method described in Japanese Patent Gazette No. 2005-21640, the measurement is performed by the following method: the injection force is dispersedly applied to the diaphragm of the force sensor arranged downstream of the nozzle, and the output from the force sensor is collected by a data acquisition device via a detection amplifier and stored as the injection force (N) according to time. The injection pressure is calculated by dividing the injection pressure measured in this way by the area of the injection port 31a of the injector. The measured value of the internal pressure of the receiving part is the same as the injection pressure, and the injection pressure can be used as the pressure inside the receiving part.
[0136] The injection energy obtained by the driving unit is transmitted to the plunger via the piston, causing the plunger to slide in the container, thereby squeezing the liquid medical composition contained in the container along the flow path formed in the nozzle unit and finally ejected from the ejection port toward the injection target.
[0137] The container may contain the liquid pharmaceutical composition from the beginning, or may not contain the liquid pharmaceutical composition. When not contained, the liquid pharmaceutical composition is contained by sucking it into the container through a nozzle having an ejection port. In this way, by adopting a structure that requires a containing operation of the container, any desired liquid pharmaceutical composition can be injected into the injection object. Therefore, in the injector in this embodiment, the syringe part and the injector body are configured to be detachable.
[0138] In this embodiment, the liquid pharmaceutical composition may be injected into the injection target by using an injector that injects the liquid pharmaceutical composition into the injection target without using an injection needle, and may be injected into the injection target by jet injection.
[0139] Here, in the present disclosure, "jet injection" refers to an injection not via an injection needle, the injection being characterized in that a liquid pharmaceutical composition comprising nucleic acids and divalent cations and having a total concentration of the divalent cations of 0.0406 mM or more and less than 81.1 mM is ejected from an ejection port toward an injection object, thereby forming a through hole that penetrates the inner and outer boundaries of the injection object, and generating a high-pressure ultrafine liquid flow that can pass through the through hole and inject the liquid pharmaceutical composition into the injection object. For example, in the case where the injection object is a mammalian individual (organism), the injection refers to an injection characterized by generating a high-pressure ultrafine liquid flow that can penetrate, for example, the skin of the mammalian individual (organism).
[0140] The injector in the present embodiment can be obtained as follows: in a previous injector that can be used to inject an injection (liquid pharmaceutical composition) into an injection object without an injection needle, the liquid pharmaceutical composition is contained in the containing portion. As such a previous injector, for example, there can be listed: an injector described in International Publication No. 2019 / 156238, an injector described in International Publication No. 2019 / 156239, an injector described in International Publication No. 2019 / 156237, an injector described in Japanese Patent No. 5989039 specification, etc. They are injectors capable of performing the jet injection, but in addition, there are many commercially available injectors (needle-free syringes) capable of performing the jet injection. For example, Straits (Pharmajet), Tropis (Pharmajet), Vitajet (Bioject Medical Technologies Inc.), Biojector 2000 (Bioject Medical Technologies Inc.), BiojectZetajet (Bioject Medical Technologies Inc.), Glide (Glide Pharma), MediJectorVision (Antares), Sumaval DosePro (Zogenix), SQ Pen (Bespak), Injex (Equidyne), hyaluronic acid injection cartridge (BEAUTTO, Amazon Standard Identification Number (ASIN): B08NCHTRHZ), etc.
[0141] Hereinafter, with reference to the accompanying drawings, a syringe 1 (needle-free syringe) will be described as an example of an injector of the present embodiment. It should be noted that the configuration of the following embodiment is an example and is not limited to the configuration of the present embodiment. It should be noted that "top end side" and "base end side" are used as terms to indicate the relative positional relationship in the length direction of the syringe 1. The "top end side" indicates a position close to the top end of the syringe 1 described later, i.e., close to the ejection port 31a, and the "base end side" indicates a direction on the opposite side of the "top end side" in the length direction of the syringe 1, i.e., the direction on the drive unit 7 side. In addition, this example is an example in which the combustion energy of the gunpowder ignited by the ignition device is used as the ejection energy for pressurization, but the present embodiment is not limited to this.
[0142] (Structure of the syringe 1)
[0143] Figure 11 is a diagram showing a schematic structure of the syringe 1, and is also a cross-sectional view of the syringe 1 along its longitudinal direction. The syringe 1 is constructed as follows: a syringe assembly 10 is mounted on a housing (syringe housing) 2, and the syringe assembly 10 is formed by integrally assembling a subassembly consisting of a syringe barrel 3 and a plunger 4 and a subassembly consisting of a syringe body 6, a piston 5, and a drive unit 7.
[0144] As described above, the syringe assembly 10 is configured to be detachable from the housing 2. The liquid medical composition is filled in the housing 32 formed between the syringe barrel 3 and the plunger 4 included in the syringe assembly 10, and the syringe assembly 10 is a unit that is used up and thrown away each time the liquid medical composition is ejected. On the other hand, the housing 2 side includes a battery 9 that supplies power to the igniter 71 included in the drive unit 7 of the syringe assembly 10. The power from the battery 9 is supplied between the electrode on the housing 2 side and the electrode on the drive unit 7 side of the syringe assembly 10 through wiring by the user pressing the button 8 provided on the housing 2. It should be noted that the shape and position of the electrode on the housing 2 side and the electrode on the drive unit 7 side of the syringe assembly 10 are designed so that the two electrodes are automatically in contact when the syringe assembly 10 is mounted on the housing 2. In addition, the housing 2 is a unit that can be used repeatedly as long as there is power remaining in the battery 9 that can be supplied to the drive unit 7. It should be noted that, in the casing 2 , when the power of the battery 9 is exhausted, only the battery 9 may be replaced and the casing 2 may continue to be used.
[0145] Next, the details of the syringe assembly 10 will be described. First, when describing the subassembly including the syringe barrel 3 and the plunger 4, the syringe barrel 3 has a receiving portion 32 formed therein as a space capable of receiving the liquid medical composition. Figure 1 As shown, the plunger 4 is configured to slide freely along the inner wall surface extending in the axial direction of the syringe barrel 3, and the inner wall surface of the syringe barrel 3 and the plunger 4 define a accommodating portion 32. In addition, the syringe barrel 3 has a nozzle portion 31 connected to the accommodating portion 32, and an ejection port 31a is formed on the top side of the nozzle portion 31. The nozzle portion 31 is a flow path whose cross-sectional area gradually decreases from the accommodating portion 32 side toward the ejection port 31a side, and is used to guide the liquid medical composition filled in the accommodating portion 32 to the ejection port 31a. Figure 1 In the example shown, the shape of the tip end side of the plunger 4 is substantially identical to the shape of the nozzle portion 31 .
[0146] Next, a subassembly including the syringe body 6, the piston 5, and the drive unit 7 will be described. The piston 5 is made of metal, for example, and is constructed to slide in a through hole formed inside the syringe body 6 by being pressurized by the combustion product (combustion gas) generated by the igniter 71 of the drive unit 7. The syringe body 6 is a roughly cylindrical member, and the piston 5 is accommodated so as to slide freely along the inner wall surface extending in its axial direction. It should be noted that the piston 5 can also be made of resin, in which case metal can also be used in the portion requiring heat resistance and pressure resistance. In addition, as Figure 1 As shown, the piston 5 is integrally connected to the plunger 4 .
[0147] Next, the driving unit 7 will be described. Figure 1 As shown, the driving unit 7 is fixed to the base end side with the through hole in the syringe body 6 as a reference. The driving unit 7 has an igniter 71 as an electric igniter. The igniter 71 is arranged in a manner facing the inside of the through hole in the syringe body 6, and ignition powder is contained therein. As the ignition powder, various gunpowders can be used as described above. In addition, the ignition powder can be contained in a gunpowder cup formed of an appropriate thin-walled metal, for example.
[0148] Next, the operation of the syringe 1 constructed as described above will be described. Figure 1 As shown, in a state where the syringe assembly 10 is mounted on the housing 2, the liquid medical composition is sucked from the ejection port 31a of the nozzle portion 31. Thus, the liquid medical composition can be filled into the housing portion 32. From this state, for example, when the ejection port 31a in the syringe 1 is brought into contact with the injection object, when the user presses the button 8 provided on the housing 2, this is used as a trigger to supply operating power from the battery 9 to the igniter 71 of the drive portion 7, and the igniter 71 operates. When the igniter 71 operates, the ignition powder is ignited and burns, generating combustion products (flame, combustion gas, etc.). As a result, for example, the gunpowder cup of the igniter 71 is cracked, and the combustion gas of the ignition powder is released into the through hole in the syringe body 6. As a result, the pressure in the through hole of the syringe body 6 rises sharply, and the piston 5 is pressed toward the top side of the syringe body 6, and as a result, the piston 5 slides toward the top side along the inner wall surface of the through hole in the syringe body 6. As described above, since the plunger 4 is integrally connected to the piston 5, the plunger 4 also slides along the inner wall surface of the syringe barrel 3 in a manner linked with the piston 5. That is, by pressing the plunger 4 into the nozzle portion 31 located at the top end side of the syringe barrel 3, the volume of the container 32 containing the liquid medical composition is reduced, and the pressure is increased rapidly. As a result, the liquid medical composition filled in the container 32 is pressed into the nozzle portion 31 and ejected from the ejection port 31a at high pressure. Thus, the liquid medical composition can be injected into the injection object.
[0149] In addition, Figure 1 Although no additional explosive component is particularly arranged in the syringe body 6 shown, in order to adjust the pressure shift applied to the liquid medical composition via the piston 5, a gas generating agent that generates gas by burning the combustion product generated by the combustion of the explosive in the igniter 71 may be arranged in the igniter 71 and in the through hole of the syringe body 6. The configuration of arranging the gas generating agent in the igniter 71 is a well-known technology as disclosed in International Publication No. 01-031282 and Japanese Patent Application Publication No. 2003-25950. In addition, as an example of the gas generating agent, a single-base smokeless powder containing 98% by mass of nitrocellulose, 0.8% by mass of diphenylamine, and 1.2% by mass of potassium sulfate can be cited. In addition, various gas generating agents used for gas generators for air bags and gas generators for seat belt pretensioners can also be used. By adjusting the size, shape, and especially the surface shape of the gas generating agent when it is arranged in the through hole, the combustion completion time of the gas generating agent can be changed, thereby, the pressure shift applied to the liquid medical composition can be set to the desired shift, that is, the shift that can make the liquid medical composition properly reach the injection object. In this embodiment, the driving part 7 also includes a gas generating agent used as needed. In this embodiment, the "pressurizing part" includes a plunger 4 and a piston 5.
[0150] Another embodiment of the present disclosure is an injector that injects a liquid medical composition into an injection target without using an injection needle, the injector comprising: a container that contains the liquid medical composition; a nozzle that is connected to the container and has an ejection port for ejecting the liquid medical composition toward the injection target; and a pressurizing portion that pressurizes the liquid medical composition contained in the container during operation, thereby ejecting the liquid medical composition from the ejection port toward the injection target, wherein the liquid medical composition contains nucleic acids and divalent cations, and the concentration of the divalent cations is greater than or equal to 0.0406 mM and less than 81.1 mM in total amount.
[0151] The injector of this embodiment is an injector described in the above embodiment that injects a liquid pharmaceutical composition into an injection target without using an injection needle, wherein the liquid pharmaceutical composition of the above embodiment is contained in the container. The description of this embodiment refers to the description of the above embodiment.
[0152] Another embodiment of the present invention is a method for injecting a liquid pharmaceutical composition into an injection object using an injector that injects the liquid pharmaceutical composition into the injection object without using an injection needle, wherein the liquid pharmaceutical composition contains nucleic acids and divalent cations, and the concentration of the divalent cations is greater than 0.0406 mM and less than 81.1 mM in total amount.
[0153] The method of this embodiment is a method of injecting the liquid pharmaceutical composition of the embodiment into a subject to be injected using an injector for injecting the liquid pharmaceutical composition into a subject to be injected without using an injection needle. The description of this embodiment refers to the description of the above embodiment.
[0154] When a liquid pharmaceutical composition is injected into a subject by the method of this embodiment, as described in the above embodiment, the physiological activity of the nucleic acid contained in the liquid pharmaceutical composition is exerted in the subject.
[0155] Therefore, the method of this embodiment may be a method for causing the physiological activity of nucleic acid to be exerted in an injected object, comprising the following steps:
[0156] The liquid pharmaceutical composition is injected into the injection object using an injector for injecting the liquid pharmaceutical composition into the injection object without using an injection needle, wherein
[0157] The liquid pharmaceutical composition contains nucleic acid and divalent cations, and the total concentration of the divalent cations is greater than or equal to 0.0406 mM and less than 81.1 mM.
[0158] Example
[0159] Although Examples are described below, all Examples are not to be construed as Examples in a limiting sense.
[0160] The following animal experiments were conducted at the Animal Experimentation Facility of the School of Medicine, Osaka University, in accordance with the Osaka University Animal Experimentation Regulations established by the Osaka University Animal Experimentation Committee.
[0161] [Test Example 1]
[0162] PBS tablets (manufactured by TAKARA BIO) (PBS(-)) were dissolved in water for injection (manufactured by Otsuka Pharmaceutical Co., Ltd.) to prepare 2x PBS, which was then sterilized by filtration. Magnesium sulfate (MgSO4·7H2O) (manufactured by Nacalai Tesque) was dissolved in the prepared 2x PBS to give a volume of 1.5:1. Figure 2 The final concentration was determined by filtration sterilization. Then, CMV-DASHER-GFP (manufactured by ATUM) (solvent: TE) (1.0 mg / mL) as a plasmid DNA containing the GFP gene was mixed at a ratio of 1:1 to prepare a liquid pharmaceutical composition. That is, the final concentration of the plasmid DNA containing the GFP gene was 0.5 mg / mL, and Mg 2+The liquid pharmaceutical composition is prepared in such a way that the final concentration (the final concentration of MgSO4·7H2O is indicated in brackets) is 0.00406mM (0.001mg / ml), 0.0406mM (0.01mg / ml), 0.406mM (0.1mg / ml), 4.06mM (1mg / ml), 40.6mM (10mg / ml) or 203mM (50mg / ml).
[0163] The prepared liquid pharmaceutical composition was used to measure the hydrodynamic diameter by dynamic light scattering (DLS) (Malvern, NANO-ZS). The average dynamic diameter was measured by preparing the measurement sample with a volume of 1.0 mL and performing it in a plastic sample cell (Cuvette). The measurement results were calculated based on the scattering intensity, and the average and standard deviation were calculated based on at least 5 different measurements.
[0164] [Comparative Test Example 1-1]
[0165] PBS tablet (manufactured by TAKARA BIO) (PBS(-)) was dissolved in water for injection (manufactured by Otsuka Pharmaceutical Co., Ltd.) to prepare 2 times PBS, which was sterilized by filtration. Then, CMV-DASHER-GFP (manufactured by ATUM) (solvent: TE) (1.0 mg / mL), which is a plasmid DNA containing the GFP gene, was mixed at a ratio of 1:1 to prepare a liquid pharmaceutical composition. That is, a final concentration of the plasmid DNA containing the GFP gene was 0.5 mg / mL, and Mg was 0. 2+ The final concentration of the liquid pharmaceutical composition was 0. The same procedure as in Test Example 1 was performed except for the above.
[0166] The results are shown in Figure 2 In Comparative Test Example 1-1, the hydrodynamic diameter is 177 nm. In contrast, in Test Example 1, as Mg 2+ The increase of Mg concentration shows a small hydrodynamic diameter. 2+ The concentration is 1mg / mL (Mg 2+ When the concentration is above 4.06 mM, the hydrodynamic diameter is about 100 nm. 2+ The increase in concentration results in electrical cross-linking within the nucleic acid and aggregation within the molecule. 2+ The concentration is 1mg / mL (Mg 2+ When the concentration is 4.06 mM or more, it is believed that the electrical cross-linking of the nucleic acid occurs sufficiently and does not lead to a further decrease in the hydrodynamic diameter.
[0167] [Comparative Test Example 1-2]
[0168] Lithium chloride (LiCl) (Nacalai Tesque) was used instead of magnesium sulfate (MgSO4·7H2O) to make Figure 3 The same method as in Experimental Example 1 was used except for the final concentration shown in FIG. + Liquid pharmaceutical compositions were prepared in such a way that the final concentration (the final concentration of LiCl is shown in brackets) was 23.59 mM (1 mg / ml) or 235.9 mM (10 mg / ml).
[0169] [Comparative Test Examples 1-3]
[0170] PBS tablet (manufactured by TAKARA BIO) (PBS(-)) was dissolved in water for injection (manufactured by Otsuka Pharmaceutical Co., Ltd.) to prepare 2 times PBS, which was sterilized by filtration. Then, CMV-DASHER-GFP (manufactured by ATUM) (solvent: TE) (1.0 mg / mL), which is a plasmid DNA containing the GFP gene, was mixed at a ratio of 1:1 to prepare a liquid pharmaceutical composition. That is, a final concentration of the plasmid DNA containing the GFP gene was 0.5 mg / mL, and Li + The liquid pharmaceutical composition with a final concentration of 0 was prepared. The same procedure as in Test Example 1 was performed except for the above. This Comparative Test Example 1-3 is substantially the same as Comparative Test Example 1-1.
[0171] The results are shown in Figure 3 In Comparative Test Example 1-3, the hydrodynamic diameter is 162 nm. In contrast, in Comparative Test Example 1-2, even though Li + The hydrodynamic diameter only changes to 153 nm with increasing concentration. This is probably because the divalent cation Mg 2+ Different, in the monovalent cation Li + No electrical cross-linking of nucleic acids occurs, and the nucleic acids are not coarsened.
[0172] From the above results, it can be seen that the presence of Mg in nucleic acid solution 2+ In this case, electrical cross-linking occurs in the nucleic acid, and the nucleic acid is coarsened.
[0173] [Test Example 2]
[0174] (Preparation of Liquid Pharmaceutical Composition)
[0175] A PBS tablet (manufactured by TAKARA BIO) (PBS(-)) was dissolved in water for injection (manufactured by Otsuka Pharmaceutical Co., Ltd.) to prepare a 2x PBS, and the mixture was sterilized by filtration. Magnesium chloride (MgCl2·6H2O, Nacalai Tesque) was dissolved in the prepared 2x PBS to a concentration twice that of the concentration when injected into 11-week-old male balb / c mice (CLEA JAPAN) as test animals, and the mixture was sterilized by filtration. Then, the mixture was mixed with CMV-DASHER-GFP (manufactured by ATUM) (solvent: TE) (1.0 mg / mL), which is a plasmid DNA containing the GFP gene, in a ratio of 1:1 to prepare a liquid pharmaceutical composition. That is, the final concentration of the plasmid DNA containing the GFP gene was 0.5 mg / mL, and the MgCl2·6H2O was dissolved in the 2x PBS to a concentration twice that of the concentration when injected into 11-week-old male balb / c mice (CLEA JAPAN) as test animals, and the mixture was sterilized by filtration. 2+ Liquid pharmaceutical compositions were prepared in such a way that the final concentration (the final concentration of MgCl2·6H2O is indicated in brackets) was 0.492 mM (0.1 mg / ml), 4.92 mM (1 mg / ml) or 49.2 mM (10 mg / ml).
[0176] (Injection into mice)
[0177] After the mice were anesthetized by inhalation of isoflurane, the hair on the back was trimmed using an electric clipper for animals. Then, the back was disinfected with alcohol, and the liquid pharmaceutical composition was injected into multiple sites on the back using the following injector. 20 μL of the liquid pharmaceutical composition was injected into each site. The injector used was Figure 1 The injector (needleless syringe) described has a nozzle diameter of 0.1 mm, 25 mg of ZPP is used as the ignition charge of the injector, and 40 mg of single-base smokeless powder (containing 98% by mass of nitrocellulose, 0.8% by mass of diphenylamine, and 1.2% by mass of potassium sulfate) is used as the gas generating agent.
[0178] (Evaluation of Gene Expression)
[0179] One day after the injection, the mouse was euthanized. Then, a skin piece of a thickness that can be observed under a microscope was collected from the back, attached to a Matsunami glass-bottomed slide, and observed using a fluorescence microscope BZ-X710 (manufactured by KEYENCE). A bright field image (exposure time: 1 / 350 s) and a fluorescent image of the GFP channel (exposure time: 1 / 20 s) were obtained, and a superimposed image (bright field image + fluorescent image) was obtained as needed.
[0180] [Comparative Test Example 2]
[0181] PBS tablet (manufactured by TAKARA BIO) (PBS(-)) was dissolved in water for injection (manufactured by Otsuka Pharmaceutical Co., Ltd.) to prepare 2 times PBS, which was sterilized by filtration. Then, CMV-DASHER-GFP (manufactured by ATUM) (solvent: TE) (1.0 mg / mL), which is a plasmid DNA containing the GFP gene, was mixed at a ratio of 1:1 to prepare a liquid pharmaceutical composition. That is, the final concentration of the plasmid DNA containing the GFP gene was 0.5 mg / mL, and the Mg content was 0.1%. 2+ Liquid pharmaceutical composition with a concentration of 0. The same procedure as in Test Example 2 was carried out except for the above.
[0182] The results are shown in Figure 4 Compared with Comparative Test Example 2, in Test Example 2, at any Mg 2+ At the concentrations of 50,000,000, obvious strong fluorescence from GFP was observed.
[0183] This result confirms that Mg exists in the nucleic acid solution. 2+ In the case of Figure 1 The described injector (needle-free syringe) has high efficiency in gene introduction and leads to high gene expression.
[0184] [Test Example 3]
[0185] A PBS tablet (manufactured by TAKARA BIO) (PBS(-)) was dissolved in water for injection (manufactured by Otsuka Pharmaceutical Co., Ltd.) to prepare a 2x PBS, and the mixture was sterilized by filtration. Magnesium sulfate (MgSO4·7H2O, Nacalai Tesque) was dissolved in the prepared 2x PBS to a concentration twice that of when injected into 11-13 week old male balb / c mice (CLEAJAPAN) as test animals, and the mixture was sterilized by filtration. Then, the mixture was mixed with CMV-DASHER-GFP (manufactured by ATUM) (solvent: TE) (1.0 mg / mL), which is a plasmid DNA containing the GFP gene, in a ratio of 1:1 to prepare a liquid pharmaceutical composition. That is, the final concentration of the plasmid DNA containing the GFP gene was 0.5 mg / mL, and the Mg was added. 2+ The liquid pharmaceutical composition is prepared in such a way that the final concentration (the final concentration of MgSO4·7H2O is indicated in brackets) is 0.00406mM (0.001mg / ml), 0.0406mM (0.01mg / ml), 0.203mM (0.05mg / ml), 0.406mM (0.1mg / ml), 4.06mM (1mg / ml), 40.6mM (10mg / ml), 81.1mM (20mg / ml) or 203mM (50mg / ml).
[0186] The injection into mice was performed in the same manner as in Experiment 2. In addition, a bright field image (exposure time: 1 / 350 s) and a fluorescent image of the GFP channel (exposure time: 1 / 20 s) were obtained, and after obtaining a superimposed image as needed, the fluorescent image was analyzed using an analysis application (Hybrid Cell Count) (manufactured by KEYENCE) as an analysis of gene expression. The analysis was performed under the conditions of brightness setting to 10 and region designation being off.
[0187] [Comparative Test Example 3]
[0188] The same procedure as in Test Example 3 was carried out except that a syringe with a 30G needle (Dentronics Needle 30G manufactured by Misawa Medical Industry Co., Ltd.) was used as the injector.
[0189] It should be noted that the following cases were also tested: no treatment (no injection of the liquid pharmaceutical composition); Figure 1 The described injector (needle-free syringe) was used as the injector, and the same liquid pharmaceutical composition (Mg) as that prepared in Comparative Test Example 2 was used. 2+ A 30G needle syringe (MISAWA MEDICAL INDUSTRY Co., Ltd. Dentronics needle 30G) was used as an injector, and the same liquid pharmaceutical composition as that prepared in Comparative Test Example 2 (Mg 2+ The concentration is 0) as the case of the liquid pharmaceutical composition.
[0190] The results are shown in Table 1. It should be noted that the "relative brightness" in the table is the same liquid pharmaceutical composition (Mg 20) prepared in Comparative Example 2 and ... 2+ The concentration is 0) and is a value obtained by converting the light intensity of the liquid pharmaceutical composition to 1.00.
[0191] When the conditions of Experimental Example 3 are compared, it is revealed that, for example, in Mg 2+ When the concentration is 0.0406 mM or more and less than 81.1 mM, the luminosity is higher than that of Mg 2+ The luminosity is high when the concentration is 0.
[0192] In addition, Mg 2+In the concentration range of 0.0406mM to 40.6mM (MgSO4·7H2O in the range of 0.01mg / ml to 10mg / ml), gene expression increased. From the results of relative luminosity (sometimes referred to as the gene expression increase rate), the maximum in Comparative Test Example 3 was about 1.6 times, while the maximum in Test Example 3 was about 7.4 times. From this result, it is clear that the presence of Mg in the nucleic acid solution 2+ The gene expression enhancement effect in the case of using Figure 1 This phenomenon is more prominent in the case of the described injector (needle-less syringe).
[0193] In addition, from the results of relative photometry, in Test Example 3, Mg 2+ In the range of 0.0406 mM to 40.6 mM concentration (0.01 mg / ml to 10 mg / ml for MgSO4·7H2O), the gene expression increase rate was a value exceeding 1. Furthermore, even in comparison with the gene expression increase rate of Comparative Test Example 3 corresponding to these ranges, Test Example 3 showed a larger value. Therefore, it can be clearly seen that the presence of Mg in the nucleic acid solution 2+ The gene expression enhancement effect in the presence of Mg 2+ This is particularly true when the concentration is in the range of 0.0406 mM to 40.6 mM (MgSO4·7H2O in the range of 0.01 mg / ml to 10 mg / ml).
[0194] [Table 1]
[0195]
[0196] [Test Example 4]
[0197] Male balb / c mice (CLEA JAPAN) aged 11-13 weeks were used as test animals, and the Mg content of the liquid pharmaceutical composition of Test Example 3 was 0.1477 g / mL. 2+ The experiment was performed in the same manner as in Experiment 3, except that the final concentration was set to 0.406 mM (MgSO4·7H2O was 0.1 mg / ml) and the mice were euthanized 6 hours, 1 day, 2 days, 3 days, 5 days, 7 days, or 14 days after the injection.
[0198] [Comparative Test Example 4-1]
[0199] The same liquid pharmaceutical composition (Mg 2+ The same procedure as in Test Example 4 was carried out except that the concentration was 0) as the liquid pharmaceutical composition.
[0200] [Comparative Test Example 4-2]
[0201] The same procedure as in Test Example 4 was carried out except that a syringe with a 30G needle (Dentronics Needle 30G manufactured by MISAWA MEDICAL INDUSTRY CO., LTD.) was used as the injector.
[0202] [Comparative Test Example 4-3]
[0203] A syringe with a 30G needle (Dentronics Needle 30G manufactured by MISAWA MEDICAL INDUSTRY Co., Ltd.) was used as an injector, and the same liquid pharmaceutical composition (Mg 2+ The same procedure as in Test Example 4 was carried out except that the concentration was 0) as the liquid pharmaceutical composition.
[0204] The results are shown in Table 2 and Figure 5 It should be noted that the “Relative luminance (1)” in the table is the value obtained by converting the luminance of Test Example 4 based on the luminance of Comparative Test Example 4-1, and the “Relative luminance (2)” is the value obtained by converting the luminance of Comparative Test Example 4-2 based on the luminance of Comparative Test Example 4-3.
[0205] From the results of Test Example 4, it can be seen that the luminosity of the liquid pharmaceutical composition was higher than that of Mg in any case from 6 hours to 14 days after injection. 2+ When the concentration is 0 (Comparative Test Example 4-1), the luminosity is large.
[0206] In addition, in Comparative Test Examples 4-2 and 4-3, only very weak GFP fluorescence was observed from 6 hours to 14 days after the injection of the liquid pharmaceutical composition, indicating weak gene expression. In Comparative Test Example 4-1, strong fluorescence was observed after 1 day, and weak fluorescence after 3 days. On the other hand, in Test Example 4, strong fluorescence was observed after 1 to 5 days, and fluorescence observation became difficult after 14 days. These results show that when using Figure 1 The gene expression period in the case of the described injector (needleless syringe) is due to the presence of Mg in the nucleic acid solution. 2+ And greatly extended.
[0207] In addition, from the results of relative luminosity (1) and relative luminosity (2) (sometimes referred to as the gene expression increase rate), in any case, the values were all greater than 1 from 6 hours to 14 days after the injection of the liquid pharmaceutical composition. Furthermore, in any case from 6 hours to 14 days after the injection of the liquid pharmaceutical composition, relative luminosity (1) showed a value greater than relative luminosity (2). Therefore, the presence of Mg in the nucleic acid solution was confirmed in any case from 6 hours to 14 days after the injection of the liquid pharmaceutical composition. 2+In particular, when using Figure 1 In the case of the described injector (needleless syringe), Mg is present in the nucleic acid solution. 2+ In the case of , the gene expression increase rate 2 days and 3 days after the injection of the liquid pharmaceutical composition exceeded 60, indicating that the gene expression was greatly improved.
[0208] [Table 2]
[0209] Table 2
[0210]
[0211]
[0212] [Test Example 5]
[0213] A PBS tablet (manufactured by TAKARA BIO) (PBS(-)) was dissolved in water for injection (manufactured by Otsuka Pharmaceutical Co., Ltd.) to prepare a 2x PBS, and the mixture was sterilized by filtration. Magnesium chloride (MgCl2·6H2O, Nacalai Tesque), magnesium nitrate (Mg(NO3)2·6H2O, Nacalai Tesque), or magnesium aspartate (Angene International Limited) was dissolved in the prepared 2x PBS to a concentration twice that of the concentration when injected into 11-week-old male balb / c mice (CLEA JAPAN) as test animals, and the mixture was sterilized by filtration. Then, the mixture was mixed with CMV-DASHER-GFP (manufactured by ATUM) (solvent: TE) (1.0 mg / mL), which is a plasmid DNA containing the GFP gene, in a ratio of 1:1 to prepare a liquid pharmaceutical composition. That is, the final concentration of the plasmid DNA containing the GFP gene was 0.5 mg / mL, and the Mg content was 0.5 mg / mL for magnesium chloride (MgCl2·6H2O). 2+ The final concentration of MgCl2·6H2O is 4.92 mM (the final concentration of MgCl2·6H2O is 1 mg / ml), and for magnesium nitrate (Mg(NO3)2·6H2O) 2+ The final concentration of Mg(NO3)2·6H2O is 3.90 mM (the final concentration of Mg(NO3)2·6H2O is 1 mg / ml), and for magnesium aspartate, Mg 2+ A liquid pharmaceutical composition was prepared in such a way that the final concentration of was 3.47 mM (the final concentration of magnesium aspartate was 1 mg / ml).
[0214] Acquisition of bright field images, fluorescence images, acquisition of superimposed images, and analysis of gene expression were performed in the same manner as in Experimental Example 2 except for the injection into mice.
[0215] [Comparative Test Example 5]
[0216] The same procedure as in Test Example 5 was carried out except that a syringe with a 30G needle (Dentronics Needle 30G manufactured by MISAWA MEDICAL INDUSTRY CO., LTD.) was used as the injector.
[0217] It should be noted that the following situations were also tested: Figure 1 The described injector (needle-free syringe) was used as the injector, and the same liquid pharmaceutical composition (Mg) as that prepared in Comparative Test Example 2 was used. 2+ A case where the concentration is 0) as the liquid pharmaceutical composition; a syringe with a 30G needle (Dentronics needle 30G manufactured by MISAWA MEDICAL INDUSTRY Co., Ltd.) is used as an injector, and the same liquid pharmaceutical composition as the liquid pharmaceutical composition prepared in Comparative Test Example 2 (Mg 2+ The concentration is 0) as the case of the liquid pharmaceutical composition.
[0218] The results are shown in Table 3 and Figure 6 The “relative brightness” in the table is the brightness of the liquid pharmaceutical composition (Mg) prepared in Experimental Example 5 and Comparative Experimental Example 5, which is the same as the liquid pharmaceutical composition prepared in Comparative Experimental Example 2. 2+ The concentration is 0) and is a value obtained by converting the light intensity of the liquid pharmaceutical composition to 1.00.
[0219] From the results of Experimental Example 5, it can be seen that the luminosity when using any magnesium salt is higher than that of Mg 2+ The luminosity is high when the concentration is 0.
[0220] In addition, when any magnesium salt is used, 2+ Compared with the case where the concentration was 0, gene expression also increased. From the results of relative luminosity (sometimes referred to as gene expression increase rate), in Test Example 5, the values were all greater than 1 when any magnesium salt was used. Furthermore, even in comparison with the gene expression increase rate of Comparative Test Example 5 corresponding to these cases, a large value was shown in Test Example 5. Therefore, it can be clearly seen that the presence of Mg in the nucleic acid solution 2+ The gene expression enhancing effect in the case of can be obtained regardless of the type of magnesium salt.
[0221] [Table 3]
[0222] Table 3
[0223]
[0224] [Test Example 6]
[0225] A PBS tablet (manufactured by TAKARA BIO) (PBS(-)) was dissolved in water for injection (manufactured by Otsuka Pharmaceutical Co., Ltd.) to prepare a 2x PBS, and the mixture was sterilized by filtration. Calcium chloride (CaCl2·2H2O, Nacalai Tesque), manganese (II) sulfate (MnSO4·5H2O, Nacalai Tesque) or lithium chloride (LiCl, Nacalai Tesque) was dissolved in the prepared 2x PBS to a concentration twice that of when injected into 11-week-old male balb / c mice (CLEAJAPAN) as test animals, and the mixture was sterilized by filtration. Then, the mixture was mixed with CMV-DASHER-GFP (manufactured by ATUM) (solvent: TE) (1.0 mg / mL), which is a plasmid DNA containing the GFP gene, in a ratio of 1:1 to prepare a liquid pharmaceutical composition. That is, the final concentration of the plasmid DNA containing the GFP gene was 0.5 mg / mL, and the CaCl2·2H2O was 0.5 mg / mL. 2+ The final concentration of CaCl2·2H2O is 1 mg / ml, and the final concentration of MnSO4·5H2O is 6.8 mM. 2+ The final concentration of MnSO4·5H2O is 4.15 mM (the final concentration of MnSO4·5H2O is 1 mg / ml), and for lithium chloride (LiCl), Li + A liquid pharmaceutical composition was prepared in such a way that the final concentration of LiCl was 23.5 mM (the final concentration of LiCl was 1 mg / ml).
[0226] Acquisition of bright field images, fluorescence images, acquisition of superimposed images, and analysis of gene expression were performed in the same manner as in Experimental Example 2 except for the injection into mice.
[0227] [Comparative Test Example 6]
[0228] The same procedure as in Test Example 6 was carried out except that a syringe with a 30G needle (Dentronics Needle 30G manufactured by MISAWA MEDICAL INDUSTRY CO., LTD.) was used as the injector.
[0229] It should be noted that the following situations were also tested: Figure 1 The described injector (needle-free syringe) was used as the injector, and the same liquid pharmaceutical composition (Ca 2+ Concentration, Mn 2+ Concentration, Li +The concentration of each liquid pharmaceutical composition is 0) as the liquid pharmaceutical composition; a syringe with a 30G needle (Dentronics needle 30G manufactured by MISAWA MEDICAL INDUSTRY Co., Ltd.) is used as an injector, and the same liquid pharmaceutical composition as the liquid pharmaceutical composition prepared in Comparative Test Example 2 is used (Ca 2+ Concentration, Mn 2+ Concentration, Li + The concentration is 0) as the liquid pharmaceutical composition.
[0230] The results are shown in Table 4 and Figure 7 The “relative brightness” in the table is the brightness of the liquid pharmaceutical composition (Ca) prepared in Experimental Example 6 and Comparative Experimental Example 6, which is the same as the liquid pharmaceutical composition prepared in Comparative Experimental Example 2. 2+ Concentration, Mn 2+ Concentration, Li + The concentrations were all 0) and were taken as values obtained by converting the light intensity of the liquid pharmaceutical composition to 1.00.
[0231] When the conditions of Test Example 6 are compared, the luminosity when calcium chloride and manganese (II) sulfate are used is greater than the luminosity when all concentrations are zero.
[0232] In addition, from the results of relative luminosity (sometimes referred to as gene expression increase rate), in Test Example 6, when calcium chloride and manganese (II) sulfate were used, the values were greater than 1. Furthermore, even in comparison with the gene expression increase rate of Comparative Test Example 6 corresponding to these cases, Test Example 6 showed a large value. Therefore, when divalent cations are present in the nucleic acid solution, the gene expression enhancement effect can be obtained, while when monovalent Li is present in the nucleic acid solution, the gene expression enhancement effect can be obtained. + In the case of , the result was that the gene expression increase rate was less than 1, and no gene expression enhancement effect was obtained. These results are very consistent with the results of DLS (Test Example 1, Comparative Test Example 1-1, Comparative Test Example 1-2, Comparative Test Example 1-3). Therefore, the following is supported: using Figure 1 The gene expression enhancing effect in the case of the described injector (needleless syringe) is a phenomenon specific to the case where divalent cations exist in the nucleic acid solution, and is caused by the coarsening of the nucleic acid.
[0233] [Table 4]
[0234] Table 4
[0235]
[0236] *1Ca 2+ Concentration, Mn 2+ Concentration, Li+ The concentration is 0
[0237] [Test Example 7]
[0238] Direct observation of the presence of Mg in nucleic acid solutions using AFM 2+ The measurement by AFM was performed using AFM5000 / AFM5300E manufactured by Hitachi High-Tech. SI-DF20S for biological samples (manufactured by Olympus) was used as the cantilever.
[0239] PBS tablets (manufactured by TAKARA BIO) (PBS(-)) were dissolved in water for injection (manufactured by Otsuka Pharmaceutical Co., Ltd.) to prepare 2x PBS, which was then sterilized by filtration. Magnesium sulfate (MgSO4·7H2O) (manufactured by Nacalai Tesque) was dissolved in the prepared 2x PBS to give a volume of 1.5:1. Figure 8 The final concentration was determined as shown, and the mixture was sterilized by filtration. Then, CMV-DASHER-GFP (manufactured by ATUM) which is a plasmid DNA containing the GFP gene was mixed (solvent: TE)
[0240] (1.0 mg / mL) was mixed in a ratio of 1:1 to prepare a liquid pharmaceutical composition. That is, the final concentration of the plasmid DNA containing the GFP gene was 0.5 mg / mL, and Mg was 0. 2+ The final concentration (the final concentration of MgSO4·7H2O in brackets) was 2.03 mM (0.5 mg / ml) or 40.6 mM (10 mg / ml) to prepare a liquid pharmaceutical composition, which was dropped onto a fresh mica surface, adsorbed for a predetermined time, and then dried by blowing air.
[0241] [Comparative Test Example 7]
[0242] PBS tablet (manufactured by TAKARA BIO) (PBS(-)) was dissolved in water for injection (manufactured by Otsuka Pharmaceutical Co., Ltd.) to prepare 2 times PBS, which was sterilized by filtration. Then, CMV-DASHER-GFP (manufactured by ATUM) (solvent: TE) (1.0 mg / mL), which is a plasmid DNA containing the GFP gene, was mixed at a ratio of 1:1 to prepare a liquid pharmaceutical composition. That is, a final concentration of the plasmid DNA containing the GFP gene was 0.5 mg / mL, and Mg was 0. 2+ The final concentration of the liquid pharmaceutical composition was 0. The same procedure as in Test Example 7 was performed except for the above.
[0243] The results are shown in Figure 8 .
[0244] In Comparative Test Example 7, a circular structure of about 200 nm was confirmed. On the other hand, particles of about 100 nm were observed in Test Example 7. These results are very consistent with the results of DLS (Test Example 1, Comparative Test Example 1-1, Comparative Test Example 1-2, Comparative Test Example 1-3), confirming the presence of Mg in the nucleic acid solution. 2+ The results support the following conclusions: the presence of Mg in nucleic acid solution 2+ In the case of Figure 1 The gene expression enhancing effect in the case of the described injector (needle-less syringe) is caused by coarsening of nucleic acid.
[0245] [Test Example 8]
[0246] In Test Example 2, a spring-loaded needleless syringe (BEAUTTO, hyaluronic acid syringe, Amazon Standard Identification Number (ASIN): B08NCHTRHZ) was used instead of Figure 1 The described injector (needleless syringe) used magnesium sulfate (MgSO4·7H2O, Nacalai Tesque Co.) instead of magnesium chloride (MgCl2·6H2O) so that the final concentration of the plasmid DNA containing the GFP gene was 0.5 mg / mL. 2+ The liquid pharmaceutical composition was prepared in such a way that the final concentration (the final concentration of MgSO4·7H2O is shown in brackets) was 2.03 mM (0.5 mg / ml) or 40.6 mM (10 mg / ml).
[0247] Acquisition of bright field images, fluorescence images, acquisition of superimposed images, and analysis of gene expression were performed in the same manner as in Experimental Example 2 except for the injection into mice.
[0248] [Comparative Test Example 8]
[0249] The same procedure as in Test Example 8 was carried out except that a syringe with a 30G needle (Dentronics Needle 30G manufactured by MISAWA MEDICAL INDUSTRY CO., LTD.) was used as the injector.
[0250] It should be noted that the following cases were also tested: the spring-type needle-free syringe was used as the injector, and the same liquid pharmaceutical composition (Mg 2+A case where the concentration is 0) as the liquid pharmaceutical composition; a syringe with a 30G needle (Dentronics needle 30G manufactured by MISAWA MEDICAL INDUSTRY Co., Ltd.) is used as an injector, and the same liquid pharmaceutical composition as the liquid pharmaceutical composition prepared in Comparative Test Example 2 (Mg 2+ The concentration is 0) as the case of the liquid pharmaceutical composition.
[0251] The results are shown in Table 5 and Fig. 9 The “relative brightness” in the table is the brightness of the liquid pharmaceutical composition (Mg) prepared in Experimental Example 8 and Comparative Experimental Example 8, which is the same as the liquid pharmaceutical composition prepared in Comparative Experimental Example 2. 2+ The concentration is 0) and is a value obtained by converting the light intensity of the liquid pharmaceutical composition to 1.00.
[0252] The results of Experiment 8 show that the presence of Mg in the nucleic acid solution 2+ The luminosity of the case is higher than that of Mg 2+ The luminosity is high when the concentration is 0.
[0253] In Experiment 8, the optimal conditions for the ejection of the spring-loaded needleless syringe were not studied, so the gene expression was kept at a low level. However, the results of relative luminosity (sometimes referred to as the gene expression increase rate) showed that the presence of Mg in the nucleic acid solution was 2+ In all cases, the values were all greater than 1. Furthermore, even in comparison with the gene expression increase rate of Comparative Test Example 8 corresponding to these cases, a large value was shown in Test Example 8. Therefore, it was shown that Mg was present in the nucleic acid solution. 2+ The gene expression enhancement effect in this case is not limited to that obtained by an injector that uses the combustion energy of the ignition charge as injection energy, but can also be obtained by a spring-type needle-free injector.
[0254] [Table 5]
[0255] Table 5
[0256]
[0257] [Test Example 9]
[0258] A PBS tablet (manufactured by TAKARA BIO) (PBS(-)) was dissolved in water for injection (manufactured by Otsuka Pharmaceutical Co., Ltd.) to prepare a 2x PBS, and the mixture was sterilized by filtration. Magnesium sulfate (MgSO4·7H2O, Nacalai Tesque) was dissolved in the prepared 2x PBS to a concentration twice that of the concentration when injected into 11-week-old male balb / c mice (CLEA JAPAN) as test animals, and the mixture was sterilized by filtration. Then, the mixture was mixed with mRNA (unmodified) encoding GFP as a reporter protein (manufactured by OZ, Funakoshi Cat#.MRNA15-100) (solvent: TE) (0.2 mg / mL) in a ratio of 1:1 to prepare a liquid pharmaceutical composition. That is, the final concentration of the mRNA encoding GFP was 0.1 mg / mL (2.0 μg per injection), and the Mg was added. 2+ Liquid pharmaceutical compositions were prepared in such a way that the final concentration (the final concentration of MgSO4·7H2O is indicated in brackets) was 2.03 mM (0.5 mg / ml), 4.06 mM (1 mg / ml), or 40.6 mM (10 mg / ml).
[0259] Acquisition of bright field images, fluorescence images, acquisition of superimposed images, and analysis of gene expression were performed in the same manner as in Experimental Example 2 except for the injection into mice.
[0260] [Comparative Test Example 9]
[0261] The same procedure as in Test Example 9 was carried out except that a syringe with a 30G needle (Dentronics Needle 30G manufactured by Misawa Medical Industry Co., Ltd.) was used as the injector.
[0262] It should be noted that the following situations were also tested: Figure 1 The described injector (needle-free syringe) was used as the injector, and the same liquid pharmaceutical composition (Mg) as that prepared in Comparative Test Example 2 was used. 2+ A case where the concentration is 0) as the liquid pharmaceutical composition; a syringe with a 30G needle (Dentronics needle 30G manufactured by MISAWA MEDICAL INDUSTRY Co., Ltd.) is used as an injector, and the same liquid pharmaceutical composition as the liquid pharmaceutical composition prepared in Comparative Test Example 2 (Mg 2+ The concentration is 0) as the case of the liquid pharmaceutical composition.
[0263] The results are shown in Table 6 and Fig.10It should be noted that the “relative brightness” in the table is the same liquid pharmaceutical composition (Mg 2 / 4) prepared in Comparative Example 2 and used in Test Example 9 and Comparative Example 9, respectively. 2+ The concentration is 0) and is a value obtained by converting the light intensity of the liquid pharmaceutical composition to 1.00.
[0264] When the conditions of Experimental Example 9 were compared, the presence of Mg in the nucleic acid solution 2+ The luminosity of the case is higher than that of Mg 2+ The luminosity is high when the concentration is 0.
[0265] In Experimental Example 9, Mg was present in the nucleic acid solution. 2+ In addition, from the results of relative luminosity (sometimes referred to as gene expression increase rate), in Experiment 9, the presence of Mg in the nucleic acid solution 2+ In all cases, the values were all greater than 1. Furthermore, even in comparison with the gene expression increase rate of Comparative Test Example 9 corresponding to these cases, Test Example 9 showed a large value. This result indicates that the presence of Mg in the nucleic acid solution 2+ In the case of Figure 1 The gene expression enhancing effect in the case of the described injector (needle-free syringe) can be obtained in nucleic acids in a broad sense including mRNA.
[0266] [Table 6]
[0267] Table 6
[0268]
[0269] [Test Example 10]
[0270] Male balb / c mice (CLEA JAPAN) aged 11-13 weeks were used as test animals, and the Mg 2+ The final concentration was set to 2.03 mM (MgSO4·
[0271] The experiment was carried out in the same manner as in Test Example 9, except that the mice were euthanized 6 hours, 1 day, 2 days, 3 days, 5 days, 7 days, or 14 days after the injection.
[0272] [Comparative Test Example 10-1]
[0273] The same liquid pharmaceutical composition (Mg 2+ The same procedure as in Test Example 10 was carried out except that the concentration was 0) as the liquid pharmaceutical composition.
[0274] [Comparative Test Example 10-2]
[0275] The same procedure as in Test Example 10 was carried out except that a syringe with a 30G needle (Dentronics Needle 30G manufactured by Misawa Medical Industry Co., Ltd.) was used as the injector.
[0276] [Comparative Test Example 10-3]
[0277] A syringe with a 30G needle (Dentronics Needle 30G manufactured by MISAWA MEDICAL INDUSTRY Co., Ltd.) was used as an injector, and the same liquid pharmaceutical composition (Mg 2+ The same procedure as in Test Example 10 was carried out except that the concentration was 0) as the liquid pharmaceutical composition.
[0278] The results are shown in Table 7 and Fig.11 It should be noted that the “Relative luminance (1)” in the table is the value obtained by converting the luminance of test example 10 based on the luminance of comparative test example 10-1, and the “Relative luminance (2)” is the value obtained by converting the luminance of comparative test example 10-2 based on the luminance of comparative test example 10-3.
[0279] The results of Test Example 10 show that the luminosity of the liquid pharmaceutical composition was higher than that of Mg in any case from 6 hours to 14 days after injection. 2+ When the concentration is 0 (Comparative Test Example 10-1), the luminosity is large.
[0280] In Comparative Test Example 10-1, strong fluorescence was observed from 6 hours later, and it became weak fluorescence after 7 days. On the other hand, in Test Example 10, strong fluorescence was observed from 6 hours to 7 days later, and it became weak fluorescence after 14 days.
[0281] In addition, from the results of relative luminosity (1) (sometimes referred to as the gene expression increase rate), in any case, from 6 hours to 14 days after the injection of the liquid pharmaceutical composition, the value was greater than 1. Furthermore, in any case from 6 hours to 14 days after the injection of the liquid pharmaceutical composition, relative luminosity (1) showed a value greater than relative luminosity (2). Figure 1 The presence of Mg in the nucleic acid solution was confirmed 6 hours to 14 days after the liquid pharmaceutical composition was injected using the described injector (needleless syringe), even when mRNA was used as the nucleic acid. 2+ The gene expression enhancement effect under the condition of .
[0282] [Table 7]
[0283] Table 7
[0284] 6 hours later 1 day later 2 days later 3 days later 5 days later 7 days later 14 days later Comparative Test Example 10-1 18476 14440 16547 7336 6703 393 1 Test Example 10 33486 35294 33438 27438 25501 16855 3 Relative luminosity(1) 1.81 2.44 2.02 3.74 3.80 42.88 4.12 Comparative Test Example 10-3 0.04 6.97 0.50 0.11 1.40 0.84 0.40 Comparative Test Example 10-2 0.05 12.38 0.60 0.10 0.53 0.77 0.29 Relative luminosity (2) 1.20 1.78 1.20 0.90 0.38 0.92 0.73
[0285] [Test Example 11]
[0286] (Preparation of Liquid Pharmaceutical Composition)
[0287] A PBS tablet (manufactured by TAKARA BIO) (PBS(-)) was dissolved in water for injection (manufactured by Otsuka Pharmaceutical Co., Ltd.) to prepare a 2x PBS, and the mixture was sterilized by filtration. Magnesium sulfate (MgSO4·7H2O, Nacalai Tesque) was dissolved in the prepared 2x PBS to a concentration twice that of the concentration when injected into 11-week-old male C57BL6 mice (CLEA JAPAN) as test animals, and the mixture was sterilized by filtration. Then, it was mixed with mRNA encoding ovalbumin (OVA) (manufactured by OZ, Funakoshi Cat#.MRNA42-100) (solvent: TE) (0.2 mg / mL) in a ratio of 1:1 to prepare a liquid pharmaceutical composition. That is, the final concentration of the mRNA encoding OVA was 0.1 mg / mL (2.0 μg per injection), and Mg 2+ A liquid pharmaceutical composition was prepared in such a way that the final concentration (the final concentration of MgSO4·7H2O is shown in brackets) was 2.03 mM (0.5 mg / ml).
[0288] (Injection into mice)
[0289] After inhalation anesthesia with isoflurane was performed on 11-week-old male C57BL6 mice, the hair on the back was trimmed using an animal electric clipper. Then, the back was disinfected with alcohol, and the liquid pharmaceutical composition was injected into two sites on the back using the following injector. 20 μL of the liquid pharmaceutical composition was injected into each site. The injector used was Figure 1 The injector (needleless syringe) described in the invention has a nozzle diameter of 0.1 mm. 25 mg of ZPP is used as the ignition charge of the injector, and 40 mg of single-base smokeless powder (containing 98% by mass of nitrocellulose, 0.8% by mass of diphenylamine, and 1.2% by mass of potassium sulfate) is used as the gas generating agent.
[0290] (ELISpot analysis)
[0291] On the 9th day after the injection of the liquid pharmaceutical composition, the mouse was euthanized and the spleen was removed. After adding the culture medium attached to the ELISpot kit (mouse IFN-γ single-color ELISPOT (manufactured by CTL)) to the removed spleen, a cell suspension was prepared using a cell filter. Then, VersaLyse hemolysis reagent (Beckman Coulter) was used for hemolysis and washing to obtain a cell dispersion of the spleen. Cell counting was performed using a disposable cell counting plate (C-Chip, Digital Bio).
[0292] Cells that reacted with the epitope peptide of the MHC class I molecule of OVA (amino acid sequence: SIINFEKL (sequence number 1), synthesized by PH Japan) and produced INF-γ were detected by ELISpot analysis (mouse IFN-γ single-color ELISPOT (manufactured by CTL)). Specifically, 100 μL of the cell dispersion was added to a predetermined number of cells (5×10 5 The cells were inoculated on a plate pre-coated with the detection antibody in the manner of 100 μL, and then the culture medium provided with the kit was used to make the total volume per well 200 μL. In the case of stimulation using an antigen, a culture medium containing 40 μg / mL of the peptide (amino acid sequence: SIINFEKL (SEQ ID NO. 1)) was used as an antigen to make the total volume per well 200 μL. The cells were then cultured overnight and the plate was colorized. The plate was colorized according to the protocol described in the kit.
[0293] [Comparative Test Example 11-1]
[0294] A PBS tablet (manufactured by TAKARA BIO) (PBS(-)) was dissolved in water for injection (manufactured by Otsuka Pharmaceutical Co., Ltd.) to prepare a 2x PBS, and the solution was sterilized by filtration. Magnesium sulfate (MgSO4·7H2O, Nacalai Tesque) was dissolved in the prepared 2x PBS to a concentration twice that of the concentration when injected into 11-week-old male C57BL6 mice (CLEA JAPAN) as test animals, and the solution was sterilized by filtration. Then, it was mixed with mRNA encoding ovalbumin (OVA) (manufactured by OZ, Funakoshi Cat#.MRNA42-100) (solvent: TE) (0.2 mg / mL) in a ratio of 1:1 to prepare a liquid pharmaceutical composition. That is, the final concentration of the mRNA encoding OVA was 0.1 mg / mL (2.0 μg per injection), and Mg was added. 2+ The liquid pharmaceutical composition with a concentration of 0 was used. Except for this, the same procedure as in Test Example 11 was performed. Figure 1The described injector (needle-free syringe) injects the mRNA encoding OVA and Mg 2+ Comparative test example of a liquid pharmaceutical composition having a concentration of 0.
[0295] [Comparative Test Example 11-2]
[0296] The same procedure as in Comparative Test Example 11-1 was performed except that a 30G needle syringe (Dentronics needle 30G manufactured by MISAWA MEDICAL INDUSTRY Co., Ltd.) was used as the injector. In other words, the mRNA encoding OVA and Mg were injected into the sample using a needle syringe. 2+ Comparative test example of a liquid pharmaceutical composition having a concentration of 0.
[0297] [Comparative Test Example 11-3]
[0298] 1x PBS was used as the liquid pharmaceutical composition. Other than that, the same procedure as in Test Example 11 was followed. Figure 1 This is a comparative test example in which a liquid pharmaceutical composition having a 1-fold concentration of PBS was injected using the described injector (needle-less syringe).
[0299] [Comparative Test Example 11-4]
[0300] A case of no treatment (a case where the liquid pharmaceutical composition was not injected) was also prepared.
[0301] [Comparative Test Example 11-5]
[0302] The same procedure as in Test Example 11 was performed except that a 30G needle syringe (Dentronics needle 30G manufactured by MISAWA MEDICAL INDUSTRY Co., Ltd.) was used as the injector. In other words, the mRNA encoding OVA and Mg were injected using a needle syringe. 2+ A comparative test example of a liquid pharmaceutical composition having a final concentration of 2.03 mM (0.5 mg / ml) (the final concentration of MgSO4·7H2O is shown in brackets).
[0303] The results are shown in Fig.12 .
[0304] First, by Fig.12 As shown in (A), in Comparative Test Example 11-2, Comparative Test Example 11-3, and Comparative Test Example 11-4, no spots were formed, and cellular immunity was not induced. On the other hand, in Comparative Test Example 11-1, many spots were formed, and cellular immunity was induced.
[0305] Then, by Fig.12As shown in (B), in Test Example 11, many spots were obviously formed, and the induction of cellular immunity was improved compared with Comparative Test Example 11-1. That is, it is speculated that even when using Figure 1 When the injection was performed in the same manner using the injector (needleless syringe) described above, the presence of Mg in the nucleic acid solution 2+ , thereby increasing the protein expression in the mouse individual (organism) and enhancing cellular immunity. Fig.12 As shown in (C), in the case of needle injection, even if there is Mg in the nucleic acid solution, 2+ , and no increase in the number of spots was confirmed.
[0306] This result makes it clear that when using Figure 1 In the case of the described injector (needleless syringe), the effect of nucleic acid vaccine can be obtained. In addition, it is clear that by the presence of Mg in the nucleic acid solution 2+ , the induction of cellular immunity is improved and the effectiveness of nucleic acid vaccines is improved.
[0307] Description of Reference Numerals
[0308] 1: syringe; 2: housing; 3: syringe barrel; 4: plunger; 5: piston; 6: syringe body; 7: drive unit; 8: button; 9: battery; 10: syringe assembly; 31: nozzle unit; 31a: ejection port; 32: storage unit; 71: igniter.
Claims
1. A liquid pharmaceutical composition, in, The liquid pharmaceutical composition comprises nucleic acid and divalent cations, The total concentration of the divalent cations is 0.0406 mM or more and less than 81.1 mM, The liquid medical composition is injected into the injection target using an injector that injects the liquid medical composition into the injection target without using an injection needle.
2. The liquid pharmaceutical composition according to claim 1, in, The divalent cation is selected from Mg 2+ , Ca 2+ , Mn 2+ and Zn 2+ One or more of the groups.
3. The liquid pharmaceutical composition according to claim 1 or 2, in, The injection into the injection target using an injector that injects the liquid pharmaceutical composition into the injection target without using an injection needle is injection into the injection target by jet injection.
4. The liquid pharmaceutical composition according to claim 1 or 2, in, The liquid pharmaceutical composition is used for inducing cellular immunity.
5. An injector for injecting a liquid pharmaceutical composition into an injection object without using an injection needle, The injector has: a containing portion containing a liquid pharmaceutical composition; a nozzle portion, connected to the containing portion, the nozzle portion having an ejection port for ejecting the liquid medical composition toward an injection object; and a pressurizing unit that, when in operation, pressurizes the liquid medical composition contained in the containing unit, thereby ejecting the liquid medical composition from the ejection port toward the injection target, The liquid pharmaceutical composition contains nucleic acid and divalent cations, and the total concentration of the divalent cations is greater than or equal to 0.0406 mM and less than 81.1 mM.
6. The injector according to claim 5, in, The divalent cation is selected from Mg 2+ , Ca 2+ , Mn 2+ and Zn 2+ One or more of the groups.
7. A method for injecting a liquid pharmaceutical composition into an injection target using an injector for injecting the liquid pharmaceutical composition into the injection target without using an injection needle, in, The liquid pharmaceutical composition contains nucleic acid and divalent cations, and the total concentration of the divalent cations is greater than or equal to 0.0406 mM and less than 81.1 mM.
8. The method according to claim 7, in, The divalent cation is selected from Mg 2+ , Ca 2+ , Mn 2+ and Zn 2+ One or more of the groups.
Citation Information
Patent Citations
Gas generator
JP2003025950A
Jet force measuring apparatus for needleless syringe
JP2005021640A
Syringe
JP2012061269A
Electric type initiator and pretensioner
WO2001031282A1
Injector
WO2019156237A1
